[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?]

Lanthier, L; Carignan, A; Plourde, M-É; Cauchon, M

[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?] / Chez des sujets de 16 ans et plus, est-ce que le vaccin BNT162b2, un vaccin à ARN messager contre la COVID-19, est efficace et sécuritaire ?

Lanthier, L; Carignan, A; Plourde, M-É; Cauchon, M.

Lanthier L; Département de médecine spécialisé, service de médecine interne générale, Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: luc.lanthier@usherbrooke.ca.
Carignan A; Département de microbiologie et d'infectiologie, Université de Sherbrooke, Sherbrooke, QC, Canada.
Plourde MÉ; Département de médecine nucléaire et radiobiologie, service de radio-oncologie, Université de Sherbrooke, Sherbrooke, QC, Canada.
Cauchon M; Département de médecine familiale et de médecine d'urgence, Université Laval, Québec, QC, Canada.

Rev Med Interne ; 42(3): 227-228, 2021 03.

Article in French | MEDLINE | ID: covidwho-1096233

Subject(s)

COVID-19 Vaccines/therapeutic use; COVID-19/therapy; Immunotherapy, Active/adverse effects; SARS-CoV-2/immunology; Adolescent; Adult; Aged; Aged, 80 and over; BNT162 Vaccine; COVID-19/epidemiology; COVID-19 Vaccines/adverse effects; Clinical Trials as Topic/methods; Clinical Trials as Topic/organization & administration; Clinical Trials as Topic/standards; Female; Follow-Up Studies; Humans; Immunotherapy, Active/methods; Immunotherapy, Active/statistics & numerical data; Male; Middle Aged; Pandemics; Patient Safety/standards; RNA, Messenger/adverse effects; RNA, Messenger/therapeutic use; SARS-CoV-2/genetics; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunotherapy, Active / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: French Journal: Rev Med Interne Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google